SEP 18, 2017 8:13 PM PDT

Scientists ID New Immunotherapy Target for Pediatric Cancer


Image credit:

By scrutinizing the physical and genetic properties of neuroblastoma, researchers from the Children's Hospital of Philadelphia say they’ve found a new target for this devastating childhood disease.

Neuroblastoma is a type of cancer that affects nerve cells in the sympathetic nervous system (PNS). This cancer is one of the most common forms of childhood cancer, affecting infants and young children. It is rarely found in children older than 10 years.

Children diagnosed with high-risk neuroblastoma, indicated by onset under 5 years of age and metastatic potential, are treated with intensive chemotherapy, surgery, radiation, and even bone marrow transplantation. In contrast, for low-risk neuroblastoma patients, doctors may opt to continuously monitor the tumor with or without surgical intervention. This method of “wait-and-see” has 90 percent prognosis rate for low-risk patients, but some deadly relapses can occur.

"Our rationale was to identify a cell-surface molecule that an immune-based therapy could target without damaging healthy tissues," explains Dr. Kristopher Bosse, the study’s lead author.

They began by sequencing the RNA in 126 neuroblastomas, and comparing that data to normal tissues.

"Using this approach, we identified a protein called glypican-2, or GPC2," says Dr. Bosse. "GPC2 is one of a family of glypicans - cell-surface proteins that interact with growth factors and cell surface receptors, influencing many intracellular signaling pathways important in development and cancer." GPC2 also helps tumors to multiply and spread.

Given the cancer-promoting properties of GPC2, the team wondered whether a drug that blocks this protein could slow the growth of neuroblastomas. Because no such drug existed, the team had to design their own compound. The result was an antibody-drug conjugate (ADC), which contains a chemotherapy agent as well as an antibody that binds to GPC2.

In human cell culture studies and in mouse models, the compound swiftly killed neuroblastoma cell “with no discernible toxicities,” they wrote. Furthermore, the team wrote the compound "showed equal efficacy with a total of 26 of 27 mice across [...] three treatment cohorts with complete and sustained tumor regression over 8 weeks."

"These findings establish that this type of immunotherapy could be potentially safe and effective [...] We have built a strong foundation for developing a completely new and hopefully much less toxic treatment for neuroblastoma, the most common cancer in infants,” said Dr. John Maris, a pediatric oncologist at the Children’s Hospital of Pennsylvania, and the study’s lead author.

"Furthermore, our findings may also lend support to the development of other immune-based therapies, such as CAR T cells, in children with multiple aggressive cancers in addition to neuroblastoma," Dr. Maris adds.

"Our next steps will be to further evaluate this ADC and also develop other immune-based therapies directed against GPC2,” said Dr. Maris. "Because other glypicans in addition to GPC2 are overexpressed in other childhood cancers, it may also be possible to apply this approach across various types of high-risk pediatric cancers."

Additional sources: MNT

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at
You May Also Like
JAN 08, 2020
Health & Medicine
JAN 08, 2020
Cancer Death Rates Declining in U.S., According to New Report
In the United States, the death rate from cancer has declined, according to a new report released today by the American Cancer Society. The video below sum...
JAN 26, 2020
JAN 26, 2020
Tumor-Highlighting Technology--Lights up Cells!
At the 56th Annual Meeting of The Society of Thoracic Surgeons, researchers announced the groundbreaking technology that can help enhance the visualization...
FEB 12, 2020
FEB 12, 2020
Can we eradicate cervical cancer within a century?
Two studies recently published in The Lancet present evidence that the eradication of cervical cancer could be possible within the next century. The World ...
FEB 24, 2020
Drug Discovery & Development
FEB 24, 2020
Leukemic Drugs May Target Lung Cancer
Two approved therapeutics for treating leukemia are currently being investigated for treatment-resistant lung cancer.  The findings were based on a li...
MAR 06, 2020
MAR 06, 2020
The lasting effects of perinatal stress
New research published in the journal Cell suggests that stress experienced during gestation in the womb, as well as immediate post-natal stress, can ...
MAR 19, 2020
MAR 19, 2020
Declining death rates for melanoma
Fewer people are dying from melanoma in the United States, suggests new research from the Perlmutter Cancer Center at NYU Grossman School of Medicine and H...
Loading Comments...